Latin Times reports that loose oversight on telehealth platforms lets patients with anorexia get weight loss drugs, and says the results have included deaths.
Recap by typeshit. Full story at Latin Times on MSN.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
Medscape walks through the basics of orforglipron, Lilly's oral GLP-1 sold as Foundayo, as the pill moves toward approval in Europe.
Reddy points to coverage cuts in Maine and Michigan and cites a study estimating $192,735 in lifetime medical savings for GLP-1 users aged 40 to 50.
Loading…